Literature DB >> 10966499

Explained and unexplained ischemic heart disease risk after renal transplantation.

Bertram L Kasiske1, Harini A Chakkera1, Joseph Roel1.   

Abstract

Whether the high incidence of ischemic heart disease (IHD) among renal transplant patients can be attributed to the same risk factors that have been identified in the general population is unclear. The risk for major IHD events occurring >1 yr after transplantation among 1124 transplant recipients was estimated by using the risk calculated from the Framingham Heart Study (FHS). The FHS risk predicted IHD (relative risk, 1.28; 95% confidence interval, 1.20 to 1.40; P: < 0.001); however, the FHS risk tended to underestimate the risk of IHD for renal transplant recipients. This was largely attributable to increased risks associated with diabetes mellitus and, to a lesser extent, age and cigarette smoking for renal transplant recipients. For men, the relative risks for diabetes mellitus were 2.78 (1.73 to 4.49) and 1.53 for the transplant recipient and FHS populations, respectively; the relative risks for age (in years) were 1.06 (1.04 to 1.08) and 1.05, respectively, and those for smoking were 1.95 (1.20 to 3.19) and 1.69, respectively. For women, the relative risks for diabetes mellitus were 5.40 (2.73 to 10.66) and 1.82, respectively. There was a tendency for the risk associated with cholesterol levels to be higher for transplant recipients, compared with the FHS population, but the risks associated with high-density lipoprotein cholesterol levels and BP appeared to be comparable. Independent of these and other risk factors, the adjusted risk of IHD for the transplant recipient population has decreased. Compared with the era before 1986, transplantation between 1986 and 1992 was associated with a lower relative risk of 0.60 (0.39 to 0.92); transplantation after 1992 was associated with an even lower relative risk of 0.27 (0.11 to 0.63) for IHD. Of concern was the fact that dihydropyridine calcium channel antagonists were associated with an increased risk for IHD (relative risk, 2.26; 95% confidence interval, 1.24 to 4.12; P: = 0. 008), and this association was independent of other antihypertensive agents and risk factors. Therefore, although the FHS risk predicts IHD after renal transplantation, it tends to underestimate the risks, especially the risk associated with diabetes mellitus. The unexpected finding that dihydropyridine calcium channel antagonists were associated with an increased IHD risk merits further evaluation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966499     DOI: 10.1681/ASN.V1191735

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  74 in total

Review 1.  Calcineurin inhibitors and post-transplant hyperlipidaemias.

Authors:  R Moore; D Hernandez; H Valantine
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Cardiovascular complications of renal disease.

Authors:  A G Jardine; K McLaughlin
Journal:  Heart       Date:  2001-10       Impact factor: 5.994

Review 3.  Challenges to achieving clinical transplantation tolerance.

Authors:  A D Salama; G Remuzzi; W E Harmon; M H Sayegh
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

4.  Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant.

Authors:  Jeffrey J Gaynor; Gaetano Ciancio; Giselle Guerra; Junichiro Sageshima; Lois Hanson; David Roth; Michael J Goldstein; Linda Chen; Warren Kupin; Adela Mattiazzi; Lissett Tueros; Sandra Flores; Luis J Barba; Adrian Lopez; Jose Rivas; Phillip Ruiz; Rodrigo Vianna; George W Burke
Journal:  Diabetologia       Date:  2014-11-01       Impact factor: 10.122

5.  Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study.

Authors:  Myra A Carpenter; Matthew R Weir; Deborah B Adey; Andrew A House; Andrew G Bostom; John W Kusek
Journal:  Clin Transplant       Date:  2012-07-09       Impact factor: 2.863

6.  Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.

Authors:  D E Weiner; M A Carpenter; A S Levey; A Ivanova; E H Cole; L Hunsicker; B L Kasiske; S J Kim; J W Kusek; A G Bostom
Journal:  Am J Transplant       Date:  2012-05-17       Impact factor: 8.086

7.  Acute rejection modulates gene expression in the collecting duct.

Authors:  Bayram Edemir; Stefan Reuter; Reka Borgulya; Rita Schröter; Ute Neugebauer; Gert Gabriëls; Eberhard Schlatter
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

8.  Statin use is associated with prolonged survival of renal transplant recipients.

Authors:  Franz Wiesbauer; Georg Heinze; Christa Mitterbauer; Franz Harnoncourt; Walter H Hörl; Rainer Oberbauer
Journal:  J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 10.121

9.  Relationships between serum lipid, lipoprotein, triglyceride-rich lipoprotein, and high-density lipoprotein particle concentrations in post-renal transplant patients.

Authors:  Elzbieta Kimak; Magdalena Hałabiś; Iwona Baranowicz-Gaszczyk
Journal:  J Zhejiang Univ Sci B       Date:  2010-04       Impact factor: 3.066

10.  Prognostic impact of SPECT-MPI after renal transplantation.

Authors:  Wael Abuzeid; Robert M Iwanochko; Xuesong Wang; S Joseph Kim; Mansoor Husain; Douglas S Lee
Journal:  J Nucl Cardiol       Date:  2016-09-23       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.